Print

Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents

A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.

Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says

All Content © 2018, Portfolio Media, Inc.